《纽约时报》报道，一项最新研究显示，单次免疫输注治疗可能在数年内持续抑制HIV病毒复制，这一发现有望彻底改变全球约3900万艾滋病感染者的治疗方式。

研究内容

该研究采用了一种基于抗体的免疫疗法，通过向患者体内输注特制抗体，激活免疫系统对HIV病毒的长期识别和清除能力。与传统抗逆转录病毒疗法（ART）需要每日服药不同，这种方法可能只需偶尔输注即可维持病毒抑制。

研究团队表示，初步临床数据显示，接受输注的患者在长达数年的观察期内，病毒载量保持在检测水平以下，且无需持续用药。

全球影响

目前全球约3900万人感染HIV，其中大部分依赖每日服药来控制病毒。如果这项技术能够通过更大规模的临床试验验证，将大幅降低治疗负担，特别是对于医疗资源有限的地区。

艾滋病领域的倡导组织i-Base称这一发现为"免疫疗法的新希望"，但同时也强调需要更多数据来确认长期疗效和安全性。

下一步

研究团队计划开展更大规模的二期临床试验，以验证疗效的持久性和不同患者群体的适用性。如果成功，这种疗法可能在数年内获得监管批准。

Single Infusion Could Suppress HIV for Years, Study Suggests

A groundbreaking study published this week suggests that a single immune-based infusion could suppress HIV replication for years, potentially transforming treatment for the roughly 39 million people living with the virus worldwide.

The research uses an antibody-based immunotherapy approach that activates the immune system to recognize and control HIV over extended periods. Unlike traditional antiretroviral therapy (ART), which requires daily medication, this method could maintain viral suppression with only occasional infusions.

Early clinical data showed that patients who received the infusion maintained undetectable viral loads for years without continuous medication. HIV advocacy group i-Base called it “a new hope for immunotherapy,” while noting that larger trials are needed to confirm long-term efficacy and safety.